Genmab and Incyte agree to colorectal cancer trial
Genmab and Incyte will collaborate on a Phase 1/2 trial combining Genmab's petosemtamab with Incyte's INCB161734 and chemotherapy for first-line colorectal cancer with KRAS G12D mutation. Genmab will lead the study, with Incyte co-funding and supplying its drug. Both companies' shares closed at $43.79 and $115.71 respectively before the announcement.
How this was made
The 30-second read
Why it matters
The announcement adds pipeline depth for both companies but lacks financial details, making immediate price moves uncertain.
Market read
Early‑stage collaboration may be viewed positively by biotech investors, but limited immediate trading impact.
What to watch
Potential competition from other KRAS G12D programs and the uncertainty of early‑stage trial outcomes.
Background
Genmab (GMAB) and Incyte (INCY) disclosed a joint first‑line colorectal cancer study targeting KRAS G12D mutations, extending petosemtamab's development.
Ticker impact
Genmab announced a new collaboration with Incyte to run a first‑line colorectal cancer trial using petosemtamab and a KRAS G12D inhibitor.
potential modest upside as investors price in the collaboration
No financial terms disclosed; impact depends on future trial results.
Incyte co‑funds and supplies its experimental KRAS G12D inhibitor for the new Genmab colorectal cancer trial.
potential modest upside as the market assesses the expanded KRAS pipeline
Collaboration details are limited; stock reaction will hinge on trial progress.
Market effects
Adds to the pipeline momentum in biotech firms developing KRAS‑targeted therapies.
Limited to US‑listed biotech investors; no broader regional effect.
Minor, as the trial is early‑stage and impacts only niche oncology investors.
Counterpoint
Without disclosed financial terms or milestones, the collaboration may not materially affect valuations.
Key entities
- companyGenmab A/S
Copenhagen‑based biotech developing antibody medicines.
- companyIncyte Corporation
U.S. biotech supplying KRAS G12D inhibitor INCB161734.
